Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

NASDAQ:RXRX   4:00:00 PM EDT
9.10
-0.01 (-0.11%)
4:07:42 PM EDT: $9.74 +0.64 (+7.03%)
Earnings Announcements

Recursion Reports Third Quarter 2022 Financial Results

Published: 11/08/2022 22:04 GMT
Recursion Pharmaceuticals Inc - Ordinary Shares - Class A (RXRX) - Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results.
Cash, Cash Equivalents $454.6 Million As of September 30, Which Excludes Proceeds From $150 Million Private Placement Offering.
Total Revenue Was $13.2 Million for Q3 of 2022, Compared to $2.5 Million for Q3 of 2021.
Qtrly Net Loss per Share of Class A and B Common Stock, Basic and Diluted $0.35.
Q3 Earnings per Share View $-0.38, Revenue View $7.0 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $27.92 Million
Adjusted EPS is expected to be -$0.25

Next Quarter Revenue Guidance is expected to be $10.38 Million
Next Quarter EPS Guidance is expected to be -$0.36

More details on our Analysts Page.